Glen MBA - Immune Therapeutics Chief Officer
| IMUNDelisted Stock | USD 0.88 0.08 10.00% |
Insider
Glen MBA is Chief Officer of Immune Therapeutics
| Age | 54 |
| Phone | 888 613 8802 |
| Web | https://www.immunetherapeutics.com |
Immune Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4526) % which means that it has lost $0.4526 on every $100 spent on assets. This is way below average. Immune Therapeutics' management efficiency ratios could be used to measure how well Immune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Immune Therapeutics currently holds 1.08 M in liabilities with Debt to Equity (D/E) ratio of 1.97, which is about average as compared to similar companies. Immune Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immune Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Immune Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immune Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immune to invest in growth at high rates of return. When we think about Immune Therapeutics' use of debt, we should always consider it together with cash and equity.
Immune Therapeutics, Inc. does not have significant operations. Immune Therapeutics, Inc. is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. Immune Therapeutics [IMUN] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). Management Performance
| Return On Asset | -0.45 |
Immune Therapeutics Leadership Team
Elected by the shareholders, the Immune Therapeutics' board of directors comprises two types of representatives: Immune Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immune. The board's role is to monitor Immune Therapeutics' management team and ensure that shareholders' interests are well served. Immune Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immune Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Glen MBA, Chief Officer | ||
| Joseph Fortunak, VP of Global RandD and Chemical Devel. and Member of Advisory Board | ||
| Peter Aronstam, CFO | ||
| FMedSci FRACP, Chief RD | ||
| Kelly Wilson, Interim Pres |
Immune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Immune Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.45 | |||
| Current Valuation | 83.25 M | |||
| Shares Outstanding | 82.76 M | |||
| Shares Owned By Insiders | 29.51 % | |||
| Price To Earning | 333.33 X | |||
| Price To Sales | 161.50 X | |||
| Gross Profit | 65.83 K | |||
| EBITDA | 3.8 M | |||
| Net Income | 3.59 M | |||
| Cash And Equivalents | 271.53 K |
Pair Trading with Immune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Immune Pink Sheet
| 0.55 | PBCRY | Bank Central Asia | PairCorr |
| 0.46 | PTAIY | Astra International Tbk | PairCorr |
| 0.38 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.36 | PBCRF | PT Bank Central | PairCorr |
The ability to find closely correlated positions to Immune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immune Therapeutics to buy it.
The correlation of Immune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Immune Pink Sheet
If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |